Annual Report 2005 - Boehringer Ingelheim

More documents

Recommendations

Info

Consumer Health Care Let’s talk about it “Constipation is a widespread and sensitive disorder. Many sufferers often feel guilty and responsible for their symptoms, believing that their lifestyle is to blame,” according to the gastroenterologist Professor Stefan A. Müller-Lissner of Park- Klinik Weissensee, Humboldt University, Berlin.
Page 1 and 2:
Value through Innovation Annual Rep
Page 3 and 4:
Contents 2 The Shareholders’ Pers
Page 5 and 6:
Value through Innovation Our vision
Page 7 and 8:
of innovative medications. Our expe
Page 9 and 10: countries since 2000 encourages us
Page 11: Shareholders’ Committee Dr Heribe
Page 14 and 15: 10 Our commitment We have committed
Page 16 and 17: 1 For our neighbours We are fundame
Page 18 and 19: 1 For our people To achieve our cor
Page 20 and 21: 1 We foster good leadership at all
Page 22 and 23: 1 For our environment In all our ac
Page 24 and 25: 0 Assessments to date show that our
Page 27 and 28: Our R&D drive Holger Pfister has be
Page 29 and 30: New data presented at the 10th Euro
Page 31 and 32: Thanks to new treatments and innova
Page 33 and 34: Laboratory assistants at our Qualit
Page 35 and 36: In addition, our discovery efforts
Page 37 and 38: the age of 65 combined with an agin
Page 39 and 40: Clinical development and registrati
Page 41 and 42: increase the planned patient number
Page 43: Business Development Our Businesses
Page 46 and 47: “spiriva® has obviously improved
Page 48 and 49: Prescription Medicines Boehringer I
Page 50 and 51: Protection around the clock “In t
Page 52 and 53: Stroke treatment and prevention Str
Page 54 and 55: 0 Serotonin and norepinephrine also
Page 56 and 57: Rheumatologic diseases Osteoarthrit
Page 58 and 59: Asia, Australasia, Africa In all ma
Page 62 and 63: A review that he led on constipatio
Page 64 and 65: 0 Consumer Health Care Our Consumer
Page 66 and 67: Margareta Ebelt collapsed in her ba
Page 68 and 69: “I did not want to become one of
Page 70 and 71: Biopharmaceuticals and Chemicals Ou
Page 72 and 73: second manufacturing process has be
Page 74 and 75: Animal Health Helping the 0
Page 76 and 77: Fortunately for Buster and the King
Page 78 and 79: Animal Health Our Animal Health div
Page 80 and 81: ➤ continued from page before 1 in
Page 82 and 83: Group Management Report Business an
Page 84 and 85: 0 The most important key figures fo
Page 86 and 87: Social responsibility Boehringer In
Page 88 and 89: Consumer Health Care (CHC) In the b
Page 90 and 91: The clear decline in the tax ratio
Page 92 and 93: Report on expected developments In
Page 94 and 95: 90 Overview of the major consolidat
Page 96 and 97: 92 C. H. Boehringer Sohn, Ingelheim
Page 102 and 103: 98 1.4 Currency conversions The fin
Page 104 and 105: 100 2.4 Provisions The provisions i
Page 106 and 107: 102 3.2 Tangible assets (in million
Page 108 and 109: 104 3.4 Inventories (in millions of
Page 110 and 111:
106 3.7 Accounts payable Residual t
Page 112 and 113:
108 Average headcount 2005 2004 Pro
Page 114 and 115:
110 The expected tax expense derive
Page 116 and 117:
112 5 Notes to the cash flow statem
Page 118 and 119:
114 Auditor’s Report We have audi
Page 120 and 121:
116 Glossary Human Pharmaceuticals
Page 122 and 123:
118 Product name Active ingredient
Page 124 and 125:
Corporate Head Office Boehringer In
Page 126:
www.boehringer-ingelheim.com
show all

Annual Report 2005 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?